SlideShare a Scribd company logo
14.06.2018
1
Fertility options for women after age of 40 years:
what is realistic, what is not?
Tevfik Yoldemir MD BSc MA
Prof. Marmara University, School of Medicine,
Dept. of Obs Gyn, Istanbul, Turkey
Adjunct Prof. Eastern Mediterranean University, School of
Medicine, Dept. of Obs Gyn, Famagusta, North Cyprus
Photo
(compulsory)
I have no financial relationships to disclose.
I have no conflict of interest.
Kaplan Meier curves for cumulative probability of pregnancy
across cycles of pregnancy attempt by age group
Fertil Steril. 2016 June ; 105(6): 1584–1588.e1. doi:10.1016/j.fertnstert.2016.02.028
Fecundability and cumulative pregnancy rates for the
cohort as calculated from survival analysis
Fertil Steril. 2016 June ; 105(6): 1584–1588.e1. doi:10.1016/j.fertnstert.2016.02.028
Fecundability and cumulative pregnancy rates by history
of prior pregnancy as calculated from survival analysis
Fertil Steril. 2016 June ; 105(6): 1584–1588.e1. doi:10.1016/j.fertnstert.2016.02.028
Which is better for live birth prediction in patients aged
over 40 with their first IVF treatment?
European Journal of Obstetrics & Gynecology and Reproductive Biology 221 (2018) 151–155
14.06.2018
2
Survey done with 196 IVF centers
Reproductive BioMedicine Online (2015) 30, 581–592 Reproductive BioMedicine Online (2015) 30, 581–592
Reproductive BioMedicine Online (2015) 30, 581–592
Frequency of various ‘poor responder’ definitions
appearing in randomized trials
Human Reproduction Update, Vol.0, No.0 pp. 1–14, 2016
doi:10.1093/humupd/dmw001
14.06.2018
3
Live birth rate per started cycle
J Assist Reprod Genet (2015) 32:931–937
Cycle cancellation per initiated cycle
Clin Exp Reprod Med 2017;44(2):111-117
https://doi.org/10.5653/cerm.2017.44.2.111
Bologna Criteria
• At least two of the following three criteria must be met to be
considered as a poor responder to COS:
(1) age 40 years or any other risk factor for poor response,
(2) a previous poor response (3 oocytes in a conventional COS cycle),
(3) an abnormal ovarian reserve test (defined as AFC < 5–7 or serum
AMH level <0.5–1.0 ng/mL)
Subgroups of POSEIDON
Reproductive Biology and Endocrinology (2018) 16:20
https://doi.org/10.1186/s12958-018-0342-1
14.06.2018
4
Human Reproduction Update, pp. 1–10, 2017
doi:10.1093/humupd/dmw047
Human Reproduction Update, pp. 1–10, 2017
doi:10.1093/humupd/dmw047
Freeze-all?
J Assist Reprod Genet (2017) 34:179–185
Freeze all
Human Reproduction, Vol.33, No.5 pp. 924–929, 2018
after the first complete cycle among 20 687 women
14.06.2018
5
accumulation of vitrified oocytes
J Assist Reprod Genet (2017) 34:479–486
accumulation of vitrified oocytes
Reproductive BioMedicine Online (2012) 24, 424– 432
Cumulative live birth rate
JAMA. 2015;314(24):2654-2662. doi:10.1001/jama.2015.17296
Strategies for women of 40+ years of age
• Tailored ovarian stimulation
• Protocol/ Gn dose & type
• Larger cohort
• Synchronous cohort
• Dual stim
• Modification of intraovarian environment
• Androgen / GH
• Embryo selection
• BT / PGS, Time-lapse
• Oocyte donation
Estimated mean number of metaphase II oocytes
required to obtain at least one euploid blastocyst
Curr Opin Obstet Gynecol 2018, 30:000–000
DOI:10.1097/GCO.0000000000000452
Human Reproduction Update, Vol.0, No.0 pp. 1–14, 2016
doi:10.1093/humupd/dmw001
14.06.2018
6
Human Reproduction Update, Vol.0, No.0 pp. 1–14, 2016
doi:10.1093/humupd/dmw001
Androgens or androgen modulating agents
Tarlatsis B, ISGE 2018
Urman B, 12th Turkish German Gynecologic Congress 2018
Future - Alternative sources of autologous oocytes
Human Reproduction, Vol.32, No.4 pp. 725–732, 2017
Future Hormonal regulation of preantral follicle growth
Endocrine Reviews, February 2015, 36(1):1–24
14.06.2018
7
Future
Endocrine Reviews, February 2015, 36(1):1–24
Future
Future Future
J Clin Endocrinol Metab, November 2016, 101(11):4405– 4412
Future
Endocrine Reviews, February 2015, 36(1):1–24
Future
JFIV Reprod Med Genet 2015, 3:3 http://dx.doi.org/10.4172/2375-4508.1000154
14.06.2018
8
Future
Hum Reprod 2001 Mar;16(3):513-6.
Case 1
• 43 year-old woman
• Recently married, BMI 20 kg/m2
• CD3 FSH 8.08 IU/L, AMH 0.8 ng/ml, AFC 10
• Curious about her fertility potential.
• What would you advise her ?
Live birth rate
Clin Exp Reprod Med 2017;44(2):111-117
https://doi.org/10.5653/cerm.2017.44.2.111
Cumulative live birth rate
Clin Exp Reprod Med 2017;44(2):111-117
https://doi.org/10.5653/cerm.2017.44.2.111
Case 2
• 40 year-old woman
• Married for 3 years, BMI 28.5 kg/m2
• CD3 FSH 8.85 IU/L, AMH 0.73 ng/ml, AFC 6
• Had 2 ICSI cycles; with poor ovarian response.
• She wants to know what might happen in the next trial?
Reproductive BioMedicine Online (2017),
doi: 10.1016/j.rbmo.2017.03.009
14.06.2018
9
Reproductive BioMedicine Online (2017),
doi: 10.1016/j.rbmo.2017.03.009
Reproductive BioMedicine Online (2017),
doi: 10.1016/j.rbmo.2017.03.009
High-dose gonadotropin stimulation with estradiol priming
Semin Reprod Med 2015;33:169–178
The protocol of double stimulation during the follicular
and luteal phases in patients with poor ovarian response
Reproductive BioMedicine Online (2014) 29, 684–691
Case 3
• 42 year-old woman
• Nulliparous, BMI 24.5 kg/m2
• Newly married ( 4 months)
• Cycle length longer than it is used to be
• CD3 FSH 17.03 IU/L, AMH 0.4 ng/ml, AFC 5
• She is worried about her chances for conception.
• How would you counsel her?
Novel POSEIDON (Patient-Oriented Strategies
Encompassing Individualized Oocyte Number) Stratification
(1) Group 1: patients younger than 35 with sufficient ovarian reserve parameters
(AFC ≥ 5, AMH ≥ 1.2 ng/ml) and with an unexpected poor or suboptimal ovarian
response;
(2) Group 2: patients older than 35 with sufficient ovarian reserve parameters (AFC
≥ 5, AMH ≥ 1.2 ng/ml) and with an unexpected poor or suboptimal ovarian
response;
(3) Group 3: patients younger than 35 with poor ovarian reserve parameters (AFC
<5, AMH <1.2ng/ml);
(4) Group 4: patients older than 35 with poor ovarian reserve parameters (AFC <5,
AMH <1.2ng/ml).
Curr Opin Obstet Gynecol 2018, 30:000–000
DOI:10.1097/GCO.0000000000000452
14.06.2018
10
“DELAYED START” PROTOCOL WITH GNRH
ANTAGONIST
Obstet Gynecol Sci 2018;61(1):102-110
https://doi.org/10.5468/ogs.2018.61.1.102
Luteal phase stimulation
Semin Reprod Med 2015;33:169–178
Minimal stimulation protocol
Semin Reprod Med 2015;33:169–178
The protocol of double stimulation during the follicular
and luteal phases in patients with poor ovarian response
Reproductive BioMedicine Online (2014) 29, 684–691
Live birth rates are satisfactory following multiple IVF
treatment cycles in poor prognosis patients
Reprod Biol (2016), http://dx.doi.org/10.1016/j.repbio.2016.11.004
Group A, 20/30/40 follicles;
group B, 13–19 follicles;
group C, 9–12 follicles;
group D, 5–8 follicles;
group E, ≤4 follicles).
Groups B and C were combined
(B/C, 9–19 follicles)
Women with FSH> 20 mIU/ml
Reproductive Sciences 1-6, 2017
DOI: 10.1177/1933719117697130
14.06.2018
11
Case 4
• 41 year-old woman
• Married for 2 years, BMI 26.5 kg/m2
• CD3 FSH 9.8 IU/L, AMH 0.08 ng/ml, AFC 4
• Has started COH for ART; only 2 follicles developed.
• She wants to know what will happen next?
In vitro fertilization versus conversion to intrauterine
insemination in Bologna-criteria poor responders
Fertil Steril2014;102:1596–601
Double ovarian stimulation protocol: both follicular and
luteal phase ovarian stimulation in the same cycle
Zhang Reproductive Biology and Endocrinology (2015) 13:76
DOI 10.1186/s12958-015-0076-2.
Case 5
• 40 year-old woman
• Married for 2 years, BMI 21 kg/m2
• CD3 FSH 4.89 IU/L, AMH 0.64 ng/ml, AFC 4
• During her previous ICSI cycle; 7 oocytes were collected, 5 were
injected and 3 fertilized and 2 embryos were transfered on D2.
• She wants to know if the next trial may be better?
tailored mode and timing of final follicular maturation
Journal of Ovarian Research (2015) 8:69
DOI 10.1186/s13048-015-0198-3
Triggering final follicular maturation- hCG,
GnRH-agonist or both, when and to whom?
Journal of Ovarian Research (2015) 8:60
DOI 10.1186/s13048-015-0187-6
GnRHa is now offered concomitant to the
standard hCG trigger dose, to improve
oocyte/embryo yield and quality.
GnRHa and hCG may be offered concomitantly,
34–37 h prior to oocyte retrieval (dual trigger)
or
40 h and 34 h prior to oocyte retrieval,
respectively (double trigger) in patients with
abnormal final follicular maturation.
14.06.2018
12
Thank you for your attention
Tevfik Yoldemir MD BSc MA
tevfik.yoldemir@marmara.edu.tr
Photo
(compulsory)

More Related Content

What's hot

How evidence can change practice
How evidence can change practiceHow evidence can change practice
How evidence can change practice
Hesham Al-Inany
 

What's hot (20)

Updates in endometrial receptivity
Updates in endometrial receptivityUpdates in endometrial receptivity
Updates in endometrial receptivity
 
4G ovarian stimulation
4G ovarian stimulation 4G ovarian stimulation
4G ovarian stimulation
 
Revealing human embryos,ragaa mansour
Revealing human embryos,ragaa mansourRevealing human embryos,ragaa mansour
Revealing human embryos,ragaa mansour
 
Ethics &amp; infertility
Ethics &amp; infertilityEthics &amp; infertility
Ethics &amp; infertility
 
How evidence can change practice
How evidence can change practiceHow evidence can change practice
How evidence can change practice
 
Day 3 vs day 5 embryo transfer
Day 3 vs day 5 embryo transferDay 3 vs day 5 embryo transfer
Day 3 vs day 5 embryo transfer
 
Low amh what next
Low amh  what nextLow amh  what next
Low amh what next
 
AMH & its Clinical Implications.pptx
AMH & its Clinical Implications.pptxAMH & its Clinical Implications.pptx
AMH & its Clinical Implications.pptx
 
Recurrent pregnancy loss
Recurrent pregnancy loss Recurrent pregnancy loss
Recurrent pregnancy loss
 
Recurrent pregnancy losses managing the unexplained
Recurrent pregnancy losses   managing the unexplainedRecurrent pregnancy losses   managing the unexplained
Recurrent pregnancy losses managing the unexplained
 
2021 Gonadotropins for controlled ovarian hyperstimulation
2021 Gonadotropins for controlled ovarian hyperstimulation2021 Gonadotropins for controlled ovarian hyperstimulation
2021 Gonadotropins for controlled ovarian hyperstimulation
 
Factors affecting success of embryo transfer
Factors affecting success of embryo transferFactors affecting success of embryo transfer
Factors affecting success of embryo transfer
 
Updates on management of Adolescent PCOS An evidence based approach
Updates on management of Adolescent PCOS An evidence based approachUpdates on management of Adolescent PCOS An evidence based approach
Updates on management of Adolescent PCOS An evidence based approach
 
Abuse
AbuseAbuse
Abuse
 
Prediction of pregnancy outcome after ICSI
Prediction  of pregnancy outcome  after ICSIPrediction  of pregnancy outcome  after ICSI
Prediction of pregnancy outcome after ICSI
 
Pitfalls in management of infertility
Pitfalls in management of infertilityPitfalls in management of infertility
Pitfalls in management of infertility
 
Recurrent pregnancy loss Presentation by Dr.Laxmi Shrikhande
Recurrent pregnancy loss Presentation by Dr.Laxmi ShrikhandeRecurrent pregnancy loss Presentation by Dr.Laxmi Shrikhande
Recurrent pregnancy loss Presentation by Dr.Laxmi Shrikhande
 
Ohss
OhssOhss
Ohss
 
Accuracy of Combined Maternal Serum Interleukin-8 and Salivary Estriol in Pre...
Accuracy of Combined Maternal Serum Interleukin-8 and Salivary Estriol in Pre...Accuracy of Combined Maternal Serum Interleukin-8 and Salivary Estriol in Pre...
Accuracy of Combined Maternal Serum Interleukin-8 and Salivary Estriol in Pre...
 
Controversies in management of Recurrent miscarriage Aboubakr Elnashar
Controversies in management of Recurrent miscarriage  Aboubakr ElnasharControversies in management of Recurrent miscarriage  Aboubakr Elnashar
Controversies in management of Recurrent miscarriage Aboubakr Elnashar
 

Similar to Fertility options after age of 40 years

Top Five Problems You Have with Ovulation Induction and How to Solve Them
Top Five Problems You Have with Ovulation Induction and How to Solve ThemTop Five Problems You Have with Ovulation Induction and How to Solve Them
Top Five Problems You Have with Ovulation Induction and How to Solve Them
Sandro Esteves
 
Intrauterine insemination versus fallopian tube sperm perfusion in non tubal ...
Intrauterine insemination versus fallopian tube sperm perfusion in non tubal ...Intrauterine insemination versus fallopian tube sperm perfusion in non tubal ...
Intrauterine insemination versus fallopian tube sperm perfusion in non tubal ...
Internet Medical Journal
 
New Developments In Reproductive Medicine
New Developments In Reproductive MedicineNew Developments In Reproductive Medicine
New Developments In Reproductive Medicine
guest7f0a3a
 
Infertility.(By Craig)
Infertility.(By Craig)Infertility.(By Craig)
Infertility.(By Craig)
drmcbansal
 

Similar to Fertility options after age of 40 years (20)

20120331 internet medical journal
20120331 internet medical journal20120331 internet medical journal
20120331 internet medical journal
 
ART for women over 40 years of age.pdf
ART for women over  40 years of age.pdfART for women over  40 years of age.pdf
ART for women over 40 years of age.pdf
 
Ovarian stimulation
Ovarian stimulation Ovarian stimulation
Ovarian stimulation
 
Management of IVF Pregnancy
Management of IVF PregnancyManagement of IVF Pregnancy
Management of IVF Pregnancy
 
In Vitro Fertilisation
In Vitro FertilisationIn Vitro Fertilisation
In Vitro Fertilisation
 
Subfertility
SubfertilitySubfertility
Subfertility
 
Eshre snapshot 2016
Eshre snapshot 2016 Eshre snapshot 2016
Eshre snapshot 2016
 
International Journal of Reproductive Medicine & Gynecology
International Journal of Reproductive Medicine & GynecologyInternational Journal of Reproductive Medicine & Gynecology
International Journal of Reproductive Medicine & Gynecology
 
Male Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and BeyondMale Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and Beyond
 
Top Five Problems You Have with Ovulation Induction and How to Solve Them
Top Five Problems You Have with Ovulation Induction and How to Solve ThemTop Five Problems You Have with Ovulation Induction and How to Solve Them
Top Five Problems You Have with Ovulation Induction and How to Solve Them
 
Optimizing IUI Outcome
Optimizing IUI OutcomeOptimizing IUI Outcome
Optimizing IUI Outcome
 
Letrozole as Ovulation Inducer
Letrozole as Ovulation InducerLetrozole as Ovulation Inducer
Letrozole as Ovulation Inducer
 
Intrauterine insemination versus fallopian tube sperm perfusion in non tubal ...
Intrauterine insemination versus fallopian tube sperm perfusion in non tubal ...Intrauterine insemination versus fallopian tube sperm perfusion in non tubal ...
Intrauterine insemination versus fallopian tube sperm perfusion in non tubal ...
 
ART Outcomes in women with endometriosis
ART Outcomes in women with endometriosisART Outcomes in women with endometriosis
ART Outcomes in women with endometriosis
 
New Developments In Reproductive Medicine
New Developments In Reproductive MedicineNew Developments In Reproductive Medicine
New Developments In Reproductive Medicine
 
Infertility.(By Craig)
Infertility.(By Craig)Infertility.(By Craig)
Infertility.(By Craig)
 
Prp & reproduction
Prp & reproductionPrp & reproduction
Prp & reproduction
 
Fresh Vs Frozen Embryo Transfer What’s The Current Practice? : Dr Sharda Jain
Fresh Vs Frozen Embryo Transfer What’s The Current Practice? : Dr Sharda Jain Fresh Vs Frozen Embryo Transfer What’s The Current Practice? : Dr Sharda Jain
Fresh Vs Frozen Embryo Transfer What’s The Current Practice? : Dr Sharda Jain
 
RHG Congress 2018 - Richard A Anderson
RHG Congress 2018 - Richard A AndersonRHG Congress 2018 - Richard A Anderson
RHG Congress 2018 - Richard A Anderson
 
Live birth by fallopian tube sperm perfusion in hyperprolactinemic woman afte...
Live birth by fallopian tube sperm perfusion in hyperprolactinemic woman afte...Live birth by fallopian tube sperm perfusion in hyperprolactinemic woman afte...
Live birth by fallopian tube sperm perfusion in hyperprolactinemic woman afte...
 

More from Marmara University School of Medicine

More from Marmara University School of Medicine (20)

Kadın Sağlığında Yapay Zeka Uygulamaları.pdf
Kadın Sağlığında Yapay Zeka Uygulamaları.pdfKadın Sağlığında Yapay Zeka Uygulamaları.pdf
Kadın Sağlığında Yapay Zeka Uygulamaları.pdf
 
ART options for poor responders.pdf
ART options for poor responders.pdfART options for poor responders.pdf
ART options for poor responders.pdf
 
Uterine Ageing.pdf
Uterine Ageing.pdfUterine Ageing.pdf
Uterine Ageing.pdf
 
Menopause Clinic.pdf
Menopause Clinic.pdfMenopause Clinic.pdf
Menopause Clinic.pdf
 
Alternative Menopausal Hormone Therapies.pdf
Alternative Menopausal Hormone Therapies.pdfAlternative Menopausal Hormone Therapies.pdf
Alternative Menopausal Hormone Therapies.pdf
 
Evaluation and Management of Endometriosis.pdf
Evaluation and Management of Endometriosis.pdfEvaluation and Management of Endometriosis.pdf
Evaluation and Management of Endometriosis.pdf
 
Artificial Intelligence and Applications on Women's Health.pdf
Artificial Intelligence and Applications on Women's Health.pdfArtificial Intelligence and Applications on Women's Health.pdf
Artificial Intelligence and Applications on Women's Health.pdf
 
Management of menopausal symptoms for breast cancer survivors
Management of menopausal symptoms for breast cancer survivorsManagement of menopausal symptoms for breast cancer survivors
Management of menopausal symptoms for breast cancer survivors
 
Health promotion for healthy aging
Health promotion for healthy agingHealth promotion for healthy aging
Health promotion for healthy aging
 
Vulvar cancer
Vulvar cancerVulvar cancer
Vulvar cancer
 
Vaginal cancer
Vaginal cancerVaginal cancer
Vaginal cancer
 
Prevention for cervial cancer
Prevention for cervial cancerPrevention for cervial cancer
Prevention for cervial cancer
 
Female sexual function dysfunction
Female sexual function dysfunctionFemale sexual function dysfunction
Female sexual function dysfunction
 
Urinary incontinence
Urinary incontinenceUrinary incontinence
Urinary incontinence
 
Pcos
PcosPcos
Pcos
 
Overactive bladder
Overactive bladderOveractive bladder
Overactive bladder
 
Vaginal cuff prolapse
Vaginal cuff prolapseVaginal cuff prolapse
Vaginal cuff prolapse
 
Pelvic organ prolapse
Pelvic organ prolapsePelvic organ prolapse
Pelvic organ prolapse
 
Infertility workup
Infertility workupInfertility workup
Infertility workup
 
Hirsutism
HirsutismHirsutism
Hirsutism
 

Recently uploaded

Mastering Wealth: A Path to Financial Freedom
Mastering Wealth: A Path to Financial FreedomMastering Wealth: A Path to Financial Freedom
Mastering Wealth: A Path to Financial Freedom
FatimaMary4
 
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdfAlcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Dr Jeenal Mistry
 

Recently uploaded (20)

Mastering Wealth: A Path to Financial Freedom
Mastering Wealth: A Path to Financial FreedomMastering Wealth: A Path to Financial Freedom
Mastering Wealth: A Path to Financial Freedom
 
Multiple sclerosis diet.230524.ppt3.pptx
Multiple sclerosis diet.230524.ppt3.pptxMultiple sclerosis diet.230524.ppt3.pptx
Multiple sclerosis diet.230524.ppt3.pptx
 
1130525--家醫計畫2.0糖尿病照護研討會-社團法人高雄市醫師公會.pdf
1130525--家醫計畫2.0糖尿病照護研討會-社團法人高雄市醫師公會.pdf1130525--家醫計畫2.0糖尿病照護研討會-社團法人高雄市醫師公會.pdf
1130525--家醫計畫2.0糖尿病照護研討會-社團法人高雄市醫師公會.pdf
 
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdfAlcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
 
ANATOMY OF THE LOWER URINARY TRACT AND MALE [Autosaved] [Autosaved].pptx
ANATOMY OF THE LOWER URINARY TRACT AND MALE [Autosaved] [Autosaved].pptxANATOMY OF THE LOWER URINARY TRACT AND MALE [Autosaved] [Autosaved].pptx
ANATOMY OF THE LOWER URINARY TRACT AND MALE [Autosaved] [Autosaved].pptx
 
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.GawadHemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
 
Impact of cancers therapies on the loss in cardiac function, myocardial fffic...
Impact of cancers therapies on the loss in cardiac function, myocardial fffic...Impact of cancers therapies on the loss in cardiac function, myocardial fffic...
Impact of cancers therapies on the loss in cardiac function, myocardial fffic...
 
The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...
The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...
The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...
 
Final CAPNOCYTOPHAGA INFECTION by Gauri Gawande.pptx
Final CAPNOCYTOPHAGA INFECTION by Gauri Gawande.pptxFinal CAPNOCYTOPHAGA INFECTION by Gauri Gawande.pptx
Final CAPNOCYTOPHAGA INFECTION by Gauri Gawande.pptx
 
Why invest into infodemic management in health emergencies
Why invest into infodemic management in health emergenciesWhy invest into infodemic management in health emergencies
Why invest into infodemic management in health emergencies
 
Young at heart: Cardiovascular health stations to empower healthy lifestyle b...
Young at heart: Cardiovascular health stations to empower healthy lifestyle b...Young at heart: Cardiovascular health stations to empower healthy lifestyle b...
Young at heart: Cardiovascular health stations to empower healthy lifestyle b...
 
Gauri Gawande(9) Constipation Final.pptx
Gauri Gawande(9) Constipation Final.pptxGauri Gawande(9) Constipation Final.pptx
Gauri Gawande(9) Constipation Final.pptx
 
The Normal Electrocardiogram - Part I of II
The Normal Electrocardiogram - Part I of IIThe Normal Electrocardiogram - Part I of II
The Normal Electrocardiogram - Part I of II
 
Compare home pulse pressure components collected directly from home
Compare home pulse pressure components collected directly from homeCompare home pulse pressure components collected directly from home
Compare home pulse pressure components collected directly from home
 
Evaluation of antidepressant activity of clitoris ternatea in animals
Evaluation of antidepressant activity of clitoris ternatea in animalsEvaluation of antidepressant activity of clitoris ternatea in animals
Evaluation of antidepressant activity of clitoris ternatea in animals
 
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
 
Fundamental of Radiobiology -SABBU.pptx
Fundamental of Radiobiology  -SABBU.pptxFundamental of Radiobiology  -SABBU.pptx
Fundamental of Radiobiology -SABBU.pptx
 
Presentació "Advancing Emergency Medicine Education through Virtual Reality"
Presentació "Advancing Emergency Medicine Education through Virtual Reality"Presentació "Advancing Emergency Medicine Education through Virtual Reality"
Presentació "Advancing Emergency Medicine Education through Virtual Reality"
 
DECIPHERING COMMON ECG FINDINGS IN ED.pptx
DECIPHERING COMMON ECG FINDINGS IN ED.pptxDECIPHERING COMMON ECG FINDINGS IN ED.pptx
DECIPHERING COMMON ECG FINDINGS IN ED.pptx
 
Effects of vaping e-cigarettes on arterial health
Effects of vaping e-cigarettes on arterial healthEffects of vaping e-cigarettes on arterial health
Effects of vaping e-cigarettes on arterial health
 

Fertility options after age of 40 years

  • 1. 14.06.2018 1 Fertility options for women after age of 40 years: what is realistic, what is not? Tevfik Yoldemir MD BSc MA Prof. Marmara University, School of Medicine, Dept. of Obs Gyn, Istanbul, Turkey Adjunct Prof. Eastern Mediterranean University, School of Medicine, Dept. of Obs Gyn, Famagusta, North Cyprus Photo (compulsory) I have no financial relationships to disclose. I have no conflict of interest. Kaplan Meier curves for cumulative probability of pregnancy across cycles of pregnancy attempt by age group Fertil Steril. 2016 June ; 105(6): 1584–1588.e1. doi:10.1016/j.fertnstert.2016.02.028 Fecundability and cumulative pregnancy rates for the cohort as calculated from survival analysis Fertil Steril. 2016 June ; 105(6): 1584–1588.e1. doi:10.1016/j.fertnstert.2016.02.028 Fecundability and cumulative pregnancy rates by history of prior pregnancy as calculated from survival analysis Fertil Steril. 2016 June ; 105(6): 1584–1588.e1. doi:10.1016/j.fertnstert.2016.02.028 Which is better for live birth prediction in patients aged over 40 with their first IVF treatment? European Journal of Obstetrics & Gynecology and Reproductive Biology 221 (2018) 151–155
  • 2. 14.06.2018 2 Survey done with 196 IVF centers Reproductive BioMedicine Online (2015) 30, 581–592 Reproductive BioMedicine Online (2015) 30, 581–592 Reproductive BioMedicine Online (2015) 30, 581–592 Frequency of various ‘poor responder’ definitions appearing in randomized trials Human Reproduction Update, Vol.0, No.0 pp. 1–14, 2016 doi:10.1093/humupd/dmw001
  • 3. 14.06.2018 3 Live birth rate per started cycle J Assist Reprod Genet (2015) 32:931–937 Cycle cancellation per initiated cycle Clin Exp Reprod Med 2017;44(2):111-117 https://doi.org/10.5653/cerm.2017.44.2.111 Bologna Criteria • At least two of the following three criteria must be met to be considered as a poor responder to COS: (1) age 40 years or any other risk factor for poor response, (2) a previous poor response (3 oocytes in a conventional COS cycle), (3) an abnormal ovarian reserve test (defined as AFC < 5–7 or serum AMH level <0.5–1.0 ng/mL) Subgroups of POSEIDON Reproductive Biology and Endocrinology (2018) 16:20 https://doi.org/10.1186/s12958-018-0342-1
  • 4. 14.06.2018 4 Human Reproduction Update, pp. 1–10, 2017 doi:10.1093/humupd/dmw047 Human Reproduction Update, pp. 1–10, 2017 doi:10.1093/humupd/dmw047 Freeze-all? J Assist Reprod Genet (2017) 34:179–185 Freeze all Human Reproduction, Vol.33, No.5 pp. 924–929, 2018 after the first complete cycle among 20 687 women
  • 5. 14.06.2018 5 accumulation of vitrified oocytes J Assist Reprod Genet (2017) 34:479–486 accumulation of vitrified oocytes Reproductive BioMedicine Online (2012) 24, 424– 432 Cumulative live birth rate JAMA. 2015;314(24):2654-2662. doi:10.1001/jama.2015.17296 Strategies for women of 40+ years of age • Tailored ovarian stimulation • Protocol/ Gn dose & type • Larger cohort • Synchronous cohort • Dual stim • Modification of intraovarian environment • Androgen / GH • Embryo selection • BT / PGS, Time-lapse • Oocyte donation Estimated mean number of metaphase II oocytes required to obtain at least one euploid blastocyst Curr Opin Obstet Gynecol 2018, 30:000–000 DOI:10.1097/GCO.0000000000000452 Human Reproduction Update, Vol.0, No.0 pp. 1–14, 2016 doi:10.1093/humupd/dmw001
  • 6. 14.06.2018 6 Human Reproduction Update, Vol.0, No.0 pp. 1–14, 2016 doi:10.1093/humupd/dmw001 Androgens or androgen modulating agents Tarlatsis B, ISGE 2018 Urman B, 12th Turkish German Gynecologic Congress 2018 Future - Alternative sources of autologous oocytes Human Reproduction, Vol.32, No.4 pp. 725–732, 2017 Future Hormonal regulation of preantral follicle growth Endocrine Reviews, February 2015, 36(1):1–24
  • 7. 14.06.2018 7 Future Endocrine Reviews, February 2015, 36(1):1–24 Future Future Future J Clin Endocrinol Metab, November 2016, 101(11):4405– 4412 Future Endocrine Reviews, February 2015, 36(1):1–24 Future JFIV Reprod Med Genet 2015, 3:3 http://dx.doi.org/10.4172/2375-4508.1000154
  • 8. 14.06.2018 8 Future Hum Reprod 2001 Mar;16(3):513-6. Case 1 • 43 year-old woman • Recently married, BMI 20 kg/m2 • CD3 FSH 8.08 IU/L, AMH 0.8 ng/ml, AFC 10 • Curious about her fertility potential. • What would you advise her ? Live birth rate Clin Exp Reprod Med 2017;44(2):111-117 https://doi.org/10.5653/cerm.2017.44.2.111 Cumulative live birth rate Clin Exp Reprod Med 2017;44(2):111-117 https://doi.org/10.5653/cerm.2017.44.2.111 Case 2 • 40 year-old woman • Married for 3 years, BMI 28.5 kg/m2 • CD3 FSH 8.85 IU/L, AMH 0.73 ng/ml, AFC 6 • Had 2 ICSI cycles; with poor ovarian response. • She wants to know what might happen in the next trial? Reproductive BioMedicine Online (2017), doi: 10.1016/j.rbmo.2017.03.009
  • 9. 14.06.2018 9 Reproductive BioMedicine Online (2017), doi: 10.1016/j.rbmo.2017.03.009 Reproductive BioMedicine Online (2017), doi: 10.1016/j.rbmo.2017.03.009 High-dose gonadotropin stimulation with estradiol priming Semin Reprod Med 2015;33:169–178 The protocol of double stimulation during the follicular and luteal phases in patients with poor ovarian response Reproductive BioMedicine Online (2014) 29, 684–691 Case 3 • 42 year-old woman • Nulliparous, BMI 24.5 kg/m2 • Newly married ( 4 months) • Cycle length longer than it is used to be • CD3 FSH 17.03 IU/L, AMH 0.4 ng/ml, AFC 5 • She is worried about her chances for conception. • How would you counsel her? Novel POSEIDON (Patient-Oriented Strategies Encompassing Individualized Oocyte Number) Stratification (1) Group 1: patients younger than 35 with sufficient ovarian reserve parameters (AFC ≥ 5, AMH ≥ 1.2 ng/ml) and with an unexpected poor or suboptimal ovarian response; (2) Group 2: patients older than 35 with sufficient ovarian reserve parameters (AFC ≥ 5, AMH ≥ 1.2 ng/ml) and with an unexpected poor or suboptimal ovarian response; (3) Group 3: patients younger than 35 with poor ovarian reserve parameters (AFC <5, AMH <1.2ng/ml); (4) Group 4: patients older than 35 with poor ovarian reserve parameters (AFC <5, AMH <1.2ng/ml). Curr Opin Obstet Gynecol 2018, 30:000–000 DOI:10.1097/GCO.0000000000000452
  • 10. 14.06.2018 10 “DELAYED START” PROTOCOL WITH GNRH ANTAGONIST Obstet Gynecol Sci 2018;61(1):102-110 https://doi.org/10.5468/ogs.2018.61.1.102 Luteal phase stimulation Semin Reprod Med 2015;33:169–178 Minimal stimulation protocol Semin Reprod Med 2015;33:169–178 The protocol of double stimulation during the follicular and luteal phases in patients with poor ovarian response Reproductive BioMedicine Online (2014) 29, 684–691 Live birth rates are satisfactory following multiple IVF treatment cycles in poor prognosis patients Reprod Biol (2016), http://dx.doi.org/10.1016/j.repbio.2016.11.004 Group A, 20/30/40 follicles; group B, 13–19 follicles; group C, 9–12 follicles; group D, 5–8 follicles; group E, ≤4 follicles). Groups B and C were combined (B/C, 9–19 follicles) Women with FSH> 20 mIU/ml Reproductive Sciences 1-6, 2017 DOI: 10.1177/1933719117697130
  • 11. 14.06.2018 11 Case 4 • 41 year-old woman • Married for 2 years, BMI 26.5 kg/m2 • CD3 FSH 9.8 IU/L, AMH 0.08 ng/ml, AFC 4 • Has started COH for ART; only 2 follicles developed. • She wants to know what will happen next? In vitro fertilization versus conversion to intrauterine insemination in Bologna-criteria poor responders Fertil Steril2014;102:1596–601 Double ovarian stimulation protocol: both follicular and luteal phase ovarian stimulation in the same cycle Zhang Reproductive Biology and Endocrinology (2015) 13:76 DOI 10.1186/s12958-015-0076-2. Case 5 • 40 year-old woman • Married for 2 years, BMI 21 kg/m2 • CD3 FSH 4.89 IU/L, AMH 0.64 ng/ml, AFC 4 • During her previous ICSI cycle; 7 oocytes were collected, 5 were injected and 3 fertilized and 2 embryos were transfered on D2. • She wants to know if the next trial may be better? tailored mode and timing of final follicular maturation Journal of Ovarian Research (2015) 8:69 DOI 10.1186/s13048-015-0198-3 Triggering final follicular maturation- hCG, GnRH-agonist or both, when and to whom? Journal of Ovarian Research (2015) 8:60 DOI 10.1186/s13048-015-0187-6 GnRHa is now offered concomitant to the standard hCG trigger dose, to improve oocyte/embryo yield and quality. GnRHa and hCG may be offered concomitantly, 34–37 h prior to oocyte retrieval (dual trigger) or 40 h and 34 h prior to oocyte retrieval, respectively (double trigger) in patients with abnormal final follicular maturation.
  • 12. 14.06.2018 12 Thank you for your attention Tevfik Yoldemir MD BSc MA tevfik.yoldemir@marmara.edu.tr Photo (compulsory)